Now that the FAA has cleared the way for commercial pilots with insulin-treated diabetes mellitus to receive first or second class medical certificates if they can prove its well-managed, this could make it easier for business aircraft pilots to return to the skies as well. “I think this is a wonderful policy that will allow professional pilots to maintain their certification while optimizing their health, said Dr. Quay Snyder, president, CEO and co-founder of Aviation Medicine Advisory Service.
In this episode of NBAA Flight Plan, host Rob Finfrock speaks with:
Dr. Clayton Cowl, chair of preventative, operational and aerospace medicine at the Mayo Clinic
Dr. Quay Snyder, president, CEO and co-founder of Aviation Medicine Advisory Service
NBAA Flight Plan is sponsored by Schedaero, the software that elevates your flight operations.
The NBAA Flight Plan podcast, which ran from 2009 to 2025, provided an overview of important developments affecting NBAA members, and the association’s work to advocate for their interest. The archive of past episodes will remain available for your enjoyment. Please note that no new episodes will be released.
The FAA has lowered wait times after an individual begins an antidepressant medication or changes, and now must wait only three months or a single, stable dose before completing required testing of the FAA antidepressant protocol.
The Department of Transportation released its 2026 testing rates for safety-sensitive positions covered by mandatory drug and alcohol testing programs, and the rates for 2026 remain unchanged from previous years.
NBAA welcomed the introduction of the Mental Health in Aviation Act and the Aviation Medication Transparency Act, which will improve transparency surrounding medication guidelines and increase access to mental health resources, while reducing the stigma surrounding such needs and protecting the livelihood of controllers and pilots.